
PSORIASIS CLINICAL PATHWAY

Adapted from Rizal Medical Center Psoriasis Clinical Pathway (2019) Reviewed by PDS Photodermatology Subspecialty Core Group (2021)



CLASSIFICATION	RIZ PSOR	IASIS CLIN	CAL CENTER IICAL PATHWAY 19)	*PDS PHOTODERM SUBSPECIALTY RECOMMENDATIONS (2021)			
	Disease Severity		Treatment	Disease Severity (Consider the highest grading)	Treatment		
MILD	MILD	PASI≤10 DLQI≤10	TOPICAL TX	BSA < 3% PASI <5	TOPICAL TX PHOTOTHERAPY and/or SYSTEMIC TX +/- TOPICAL TX		
	WILD	PASI≤10 DLQI≥10		DLQI <5			
MODERATE	RATE) ERE	PASI >10 DLQI ≤10	PHOTOTHERAPY and/or SYSTEMIC TX +/- TOPICAL TX	BSA 3% - 10% PASI 5 - 10 DLQI 5 - 10			
SEVERE	MODERATE TO SEVERE	PASI >10 DLQI >10		BSA >10% PASI >10 DLQI >10			
ERYTHRODERMIC or gpp	(BSA) (DLQI) +(PRO) + Patient reported outcomes		SYSTEMIC TX +/- TOPICAL TX		SYSTEMIC TX +/- TOPICAL TX		

*IMAFUKU, S. et.al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. Journal of Dermatology 2018 Ministry of Health. June 2013. Clinical Practice Guidelines: Management of Psoriasis Vulgaris. Malaysia Health Technology Assessment Section (MaHTAS). Putrajaya Malaysia

TOPICAL THERAPY FOR PSORIASIS:

Trunk and Limbs

Initial Treatment:

* Potent corticosteroid OD-BID X 4 weeks OR * Very potent corticosteroid (for rapid response & only for limited plaques) OD-BID X 2 weeks OR Potent corticosteroid OD and vitamin D or vitamin D analogue OD (separately) x 4 weeks.

* VP or P CS Max. 50 g/week

— 2-4 weeks

If no clearance, near clearance or satisfactory control, ** vitamin D or a vitamin D analogue alone BID.

** Max.100 g/week

—— 8-12 weeks

If no clearance, near, clearance or satisfactory control after 8–12 weeks offer either: • combined product: *** calcipotriol monohydrate and betamethasone dipropionate OD x 4 weeks.

*** Max. 15 g daily or 100 g weekly

Adjunct topicals: Emollients, Tar, Salicylic acid

Face, Genitals, Flexures

Initial Treatment:

Mild or moderate potency corticosteroid BID x 2 weeks.

- 2 weeks

For adults with psoriasis of the **face, flexures or genitals** if the response to short-term moderate potency corticosteroids is unsatisfactory, or they require continuous treatment to maintain control and there is serious risk of local corticosteroid-induced side effects, offer a **calcineurin inhibitor BID x 4 weeks**.

If treatment is unsatisfactory, please see phototherapy or systemic treatment pathway.

 Suggested reassessment : initial review after 4 weeks; treatment unsatisfactory- if no control after 12 weeks

 National Institute for Health and Care Excellence (2017) Assessment and Management of Psoriasis (NICE Guideline 153)

 Ministry of Health. June 2013. Clinical Practice Guidelines: Management of Psoriasis Vulgaris. Malaysia Health Technology

 Assessment Section (MaHTAS). Putrajaya Malaysia

 Printed (June 2022)

Initial Treatment:

Potent corticosteroid solution OD × 4 weeks OR Very potent corticosteroid (for rapid response and only for limited plaques) BID × 2 weeks.

Scalp

— 2-4 weeks

If no clearance, near clearance or satisfactory control after **4 weeks** consider:

• a different formulation of the potent corticosteroid (for example, a shampoo) **and/or**

• topical agents to remove adherent scale before application of the potent corticosteroid.

— 4 weeks

If response remains unsatisfactory after a further **4 weeks** of treatment offer:

• a combined product **containing calcipotriol monohydrate and betamethasone dipropionate OD** for up to **4 weeks**.


— 4 weeks

If continuous treatment for up to **8 weeks** does not result in clearance, near clearance or satisfactory control offer:

• a very potent corticosteroid solution BID × 2 weeks.

PHOTOTHERAPY:

For patients with moderate or severe psoriasis (including subacute to chronic exfoliative dermatitis) or if topical treatment is unsatisfactory



If treatment is unsatisfactory or poorly tolerated; there is *rapid relapse following completion of treatment; accessing treatment is difficult for logistical reasons; or patient is at high risk of skin cancer, **Please see SYSTEMIC pathway.**

Suggested reassessment – after 12 weeks

*Rapid relapse is defined as greater than 50% of baseline disease severity within 3 months. National Institute for Health and Care Excellence (2017) Assessment and Management of Psoriasis (NICE Guideline 153)

SYSTEMIC NON-BIOLOGIC THERAPY:

For patients with moderate or severe psoriasis, or if phototherapy +/- topical tx is unsatisfactory. All patients who will undergo systemic treatment should have normal baseline screening.

Methotrexate

Cyclosporine

Initial drug of choice

Dosage:

Incremental dosing of methotrexate starting with an initial dose of **5-10 mg once a** week and gradually increase up to an effective dose. Maximum is **25 mg a week.**

Use the lowest possible therapeutic dose of methotrexate to maintain remission.

Supplement with **folic acid** 5 mg once a day (except the day of methotrexate) or 5mg once a week (the day after methotrexate)

Assess tx after 3 months at the target dose

Please see pathway for monitoring AE.

For short term control (e.g. psoriatic flare, erythrodermic, generalized pustular)
Palmoplantar pustulosis
Considering conception (men and women)

Dosage:

Use **2.5-3 mg/kg** a day of cyclosporine. **Escalate** to **5 mg/kg a day after 4 weeks** only when there is no response to the lower dose or when rapid disease control is necessary.

Use the lowest possible therapeutic dose of cyclosporine to maintain remission for **1 year.** Consider other treatment options when disease relapses rapidly on stopping cyclosporine therapy*

Do not use cyclosporine continuously for more than 1 year unless disease is severe or unstable and other treatment options, including systemic biological therapy, cannot be used.

Assess tx after 3 months at the target dose

Acitretin

- Pustular psoriasis (1st line)
- If methotrexate and cyclosporine are not appropriate or failed

Dosage

Use incremental dosing of acitretin to minimize mucocutaneous side effects and achieve a target dose of **25 mg** daily in adults. Consider dose escalation to a maximum of **50 mg OD** when no other treatment options are available.

Assess tx after 4 mons at the target dose

If treatment is unsatisfactory or poorly tolerated, please see biologics pathway


Suggested reassessment – after 12 weeks

*Rapid relapse is defined as greater than 50% of baseline disease severity within 3 months. Ministry of Health. June 2013. Clinical Practice Guidelines: Management of Psoriasis Vulgaris. Malaysia Health Technology Assessment Section (MaHTAS). Putrajaya Malaysia

National Institute for Health and Care Excellence (2017) Assessment and Management of Psoriasis (NICE Guideline 153)

Printed (June 2022)

MONITORING:



Ministry of Health. June 2013. Clinical Practice Guidelines: Management of Psoriasis Vulgaris. Malaysia Health Technology Assessment Section (MaHTAS). Putrajaya Malaysia **Printed (June 2022)**

OTHER SYSTEMIC AGENTS FOR PSORIASIS:

NOTE: These medications are NOT FDA-approved for psoriasis. May have value for psoriasis in certain instances.

Available in the Philippines

HYDROXYUREA
MYCOPHENOLATE MOFETIL
AZATHIOPRINE
TOFACITINIB
TACROLIMUS
ISOTRETINOIN

Not Available in the Philippines AS OF 2021

THIOGUANINELEFLUNOMIDEFUMARIC ACID ESTERS

• Apremilast – FDA approved, not yet available in the Philippines



Sources:


- Menter A. et.al. Joint American Academy of Dermatology National Psoriasis Foundation Guidelines of care for the management of psoriasis with systemic nonbiologic therapies. JOURNAL OF AMERICAN ACADEMY OF DERMATOLOGY. JUNE 2020, Vol. 82, No.6:1445-86. https://doi.org/10.1016/j.jaad.2020.02.044
- + Chu S. et.al. Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions. ARCHIVES OF DERMATOLOGICAL RESEARCH. NOV. 2020. doi: 10.1111/1346-8138.14338

Printed (June 2022)

SYSTEMIC BIOLOGIC TREATMENT:

For patients with moderate or severe psoriasis, or if other treatment modalities are unsatisfactory.

All patients who will undergo systemic treatment should have normal baseline screening.



+ National Psoriasis Foundation 2021, accessed 22 June 2022, <https://www.psoriasis.org/advance/cosentyx-receives-pediatric-indication/> Ministry of Health. June 2013. Clinical Practice Guidelines: Management of Psoriasis Vulgaris. Malaysia Health Technology Assessment Section (MaHTAS). Putrajaya Malaysia

Printed (June 2022)

BASELINE SCREENING FOR SYSTEMIC TREATMENT:

HISTORY AND EXAMINATION:

For the following established or suspected conditions, clear with specialist or give alternative treatment:

1) Tuberculosis (TB) (Internal Medicine/ Infectious disease/Pulmonologist)

- 2) Malignancy
- 3) Active infection other than TB, HIV-AIDS or viral hepatitis
- 4) HIV-AIDS (HACT team)
- 5) Hepatitis B or C
- 6) Congestive heart failure
- 7) Demyelinating disease
- 8) Pregnancy, Desire for pregnancy, or Breast-feeding



Printea

une 20

BASELINE SCREENING FOR SYSTEMIC TREATMENT:

REQUIRED INITIAL LABORATORY TESTS:

- CBC
- AST & ALT
- Creatinine
- * Chest X-ray
- * PPD Test

*Screening for TB: If symptomatic or with hx of PTB or any CXR

abnormalities in the past

→ DO CXR. Otherwise, do PPD Test.

OPTIONAL LABORATORY TESTS, IF CLINICALLY INDICATED:

- ESR/CRP
- Urinalysis
- Lipid profile
- Fasting blood sugar
- Interferon gamma release assay (TB Quantiferon)
- HBsAg Required prior to biologic use (If positive, refer to Gastoenterologist)
- · Hepatitis B core antibody- If positive refer Gastroenterologist
- · HCV Ab If positive refer Gastroenterologist
- ANA If positive to refer Rheumatologist
- Urine pregnancy test (UPT)
- COVID-19 TEST (as indicated)

PATIENT EDUCATION & COUNSELING

PSORIASIS CLINIC CHECKLIST (IST VISIT)

		1ST VISI	T DATE:	
PROCESS	OUTPATIENT PSORIASIS CLINIC			REMARKS
	OUTPATIENT PSORIASIS CEINIC			REMARKS
		YES	NO	
	Current and previous history of TB infection			
	Current and previous history of malignancy			
	Active infection			
HISTORY TAKING /	HIV infection			
	Hepatitis B/Hepatitis C infection			
CHECK FOR	Congestive heart failure			
COMORBIDITIES /	Demyelinating disease			
	Pregnancy			
PSORIATIC ARTHRITIS	(For women) Intention to get pregnant			
	Currently breastfeeding			
	Check for joint pains			
	Vital signs (BP, PR, RR, Temp)			
	Weight/BMI			
	Skin Examination			
PHYSICAL	Nail Examination			
PHISICAL	Hair/scalp examination			
EXAMINATION	Examination of joints			
	PASI score			
	DLQI score			
	Skin biopsy (if indicated)			
	REQUIRED INITIAL ANCILLARIES:			
	CBC			
	AST & ALT Creatinine			
DIAGNOSTICS /	OPTIONAL ANCILLARIES:			
LABORATORIES /	ESR/CRP			
	Urinalysis			
RADIOLOGIC	Lipid profile			
EXAMINATION	Fasting blood sugar			
EXAMINATION	HBsAg			
	Hepatitis B core Ab			
	HCVAb			
	ANA			
	PPD Test			
	Interferon gamma release assay			
	Urine Pregnancy Test			
	Topical medications (as indicated)			
THERADELITICS	Phototherapy (as indicated)			
THERAPEUTICS	Non-biologic systemic oral/parenteral medication (as indicated)			
	Biologic medication (as indicated)			
	Diet/Nutrition			
	Weight reduction (if necessary)			
PATIENT EDUCATION	Smoking cessation (if necessary)			
	Regular exercise			
	Rheumatology (psoriatic arthritis)			
	Endocrinology (diabetes mellitus)			
	Cardiology (hypertension, cardiovascular disease)			
	Gastroenterology (IBD)			
DEFEDRALC	Pulmonology (pulmonary TB)			
REFERRALS	Pediatrics (pediatric cases)			
as needed for management of comorbidities/ complications/	Pediatric special recases) Pediatric rheumatology (pediatric patient with psor arthritis)			
need for financial assistance)	Ophthalmology (uveitis)			
	Mental health / Psychiatry (depression)			
	Dietician / Nutritionist (overweight/obese)			
	Rehab medicine (complications of psoriatic arthritis)			
501101115	Social service (financial assistance)		-	
FOLLOW-UP	Appointment schedule			

PSORIASIS CLINIC CHECKLIST (FOLLOW-UP)

PROCESS	OUTPATIENT PSORIASIS CLINIC	VISIT NO.).		VISI			
		мм	DD	11111	REMARKS	мм	DD	****	REMARKS
		YES	5	NO		YES	5	NO	
HISTORY TAKING	Ask for associated symptoms								
	Review of systems								
	Check for joint pains								
	Vital signs (BP, PR, RR, Temp)								
	Weight/BMI								
	Skin Examination								
PHYSICAL	Nail Examination								
EXAMINATION	Hair/scalp examination								
	Examination of joints								
	PASI score								
	DLQI score								
	On Methotrexate:								
	CBC								
	AST & ALT								
	Creatinine								
DIAGNOSTICS / LABORATORIES / RADIOLOGIC EXAMINATION	Fibroscan (if indicated)								
	Liver biopsy (if indicated)								
	On Cyclosporine:								
	CBC								
	AST & ALT								
	Creatinine								
	Serum bilirubin (if indicated)								
	Magnesium (if indicated)								
	On Acitretin:								
	AST & ALT								
	Lipid profile								
THERAPEUTICS	Topical medications (if indicated)								
	Phototherapy (if indicated)								
	Non-biologic systemic								
	oral/parenteral medication (if indicated)								
	Biologic medication (if indicated)								
PATIENT EDUCATION	(as indicated)		-						
REFERRALS	(as indicated)								
FOLLOW-UP	Appointment schedule		_						
DISCHARGE	Review the checklist and pathway								winted (June 2)

ACKNOWLEDGMENT

RIZAL MEDICAL CENTER - TECHNICAL WORKING GROUP

Lily Lyralin Laconico Tumalad, MD, FPDS Rogelio A. Balagat, MD, FPCP, FPDS, FPRA Alma Gay C. Amado, MD, FPDS Martha Joy Bruan-Tapales, MD, FPDS Francisco D. Rivera IV, MD, FPDS Dr. Ian Cabaluna (Epidemiologist)

PDS Photodermatology Subspecialty Core Group:

Leilani R. Senador, MD, FPDS (Chair 2021 -2022)

Bernadette B. Arcilla, MD, FPDS Ma. Lorna F. Frez, MD, FPDS Vermen M. Verallo- Rowell, MD, FPDS Patricia Anne T. Tinio, MD, FPDS Bernardita Ortiz-Policarpio, MD, FPDS Maria Deanna S. Ramiscal, MD, FPDS Vanessa M. Carpio, MD, FPDS Lily Lyralin L. Tumalad, MD, FPDS Pearl Weena Marie E. Sabido, MD, FPDS Giselle Marie T. Ver, MD, FPDS Luella Joy A. Escueta-Alcos, MD, FPDS Angelica I. Guzman-Hernandez, MD, FPDS Ria Carla C. Siccion, MD, FPDS Anna Lou Castro Diaz, MD, FPDS Ma. May Jasmin R. Yason, MD, FPDS Maria Rosa Noliza F. Encarnacion, MD, DPDS Corrine Sison-De Jesus, MD, DPDS Angeli Eloise E. Torres, MD, DPDS